Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 2 · 33.3%High 3 · 50%

Once daily dosing vs conventional dosing

Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.94 [0.88, 1.01]
10 studies · 3910 participants
High

Once daily dosing vs conventional dosing

Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.18 [0.72, 1.93]
9 studies · 2306 participants
Moderate

Once daily dosing vs conventional dosing

Adverse event · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
8 studies · 3497 participants
High

Once daily dosing vs conventional dosing

Serious adverse events · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.2 [0.77, 1.87]
7 studies · 3196 participants
Moderate

Once daily dosing vs conventional dosing

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.18 [0.74, 1.89]
8 studies · 4340 participants
Very low

Once daily dosing vs conventional dosing

Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.99 [0.85, 1.15]
7 studies · 3737 participants
High